medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-10-78-82medsovet-2536Research ArticleОнкоурологияOncourologyТерапия препаратом радий-223 больных с костными метастазами кастрационно-резистентного рака предстательной железыRadium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastasesКапринА. Д.KaprinA. D.

Академик РАН, доктор медицинских наук, профессор

Moscow

КостинА. А.KostinA. A.

Доктор медицинских наук

Moscow

ВоробьевН. В.VorobyevN. V.

Кандидат медицинских наук

Moscow

ПоповС. В.PopovS. V.

Доктор медицинских наук, профессор

Moscow

ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России; Российский университет дружбы народовРоссияNational Medical Research Radiological Center, Federal State Budgetary Institution of the Ministry of Health of Russia; Russian Peoples’ Friendship UniversityRussian FederationФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииРоссияNational Medical Research Radiological Center, Federal State Budgetary Institution of the Ministry of Health of RussiaRussian Federation2018180720180107882Copyright © Каприн А.Д., Костин А.А., Воробьев Н.В., Попов С.В., 20182018Каприн А.Д., Костин А.А., Воробьев Н.В., Попов С.В.Kaprin A.D., Kostin A.A., Vorobyev N.V., Popov S.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2536

Развитие резистентности к гормональной терапии и прогрессирование опухолевого процесса у больных раком предстательной железы ассоциируются с неблагоприятным прогнозом. В статье представлен обзор результатов клинических исследований эффективности и безопасности, а также опыта применения в клинической практике радиоизотопного препарата радия-223 хлорида у больных с костными метастазами при кастрационно-резистентном раке предстательной железы без висцеральных метастазов. Показано, что терапия радия-223 хлоридом у данной категории больных приводит к увеличению общей выживаемости и времени до развития костных осложнений, а также характеризуется хорошей переносимостью.

The development of resistance to endocrine therapy and the tumor progression in patients with prostate cancer are associated with an unfavourable prognosis. The article presents a review of clinical trials of efficacy and safety, as well as the experience in using radioisotope radium-223 chloride in clinical practice in patients with castration-resistant prostate cancer with bone metastases without visceral metastases. It was shown that radium-223 chloride therapy in this category of patients leads to an increase in overall survival and time to the development of bone complications, and is characterized by good tolerability.

рак предстательной железыкастрационная резистентностькостные метастазырадий-223эффективностьбезопасностьклиническая практикаprostate cancercastration resistancebone metastasesradium-223efficacysafetyclinical practiceReferencesПод редакцией Каприна А.Д., Старинского В.В., Петровой Г.В. Состояние онкологической помощи населению России в 2016 году. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 236 с.Edited by Kaprin A, Starinsky VV, Petrova GV. Status of oncological care for the population of Russia in 2016. Moscow: P.A. Herzen Moscow Cancer Research Institute, a branch of the National Medical Research Radiological Center of the Ministry of Health of Russia, 2017. 236 p.Guidelines on Prostate Cancer. European Association of Urology EAU, 2017. 146 p.Guidelines on Prostate Cancer. European Association of Urology EAU, 2017. 146 p.Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 2008, 26: 242-245.Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 2008, 26: 242-245.Матвеев В.Б., Маркова А.С. Радий-223 в лечении кастрационно-резистентного рака предстательной железы с метастазами в кости. Онкоурология, 2017, 13(3): 140-147./Matveev VB, Markova AS. Radium-223 in the treatment of castration-resistant prostate cancer with bone metastases. Onkourologya, 2017, 13 (3): 140-147.Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res, 2013, 19(21): 5822–5827.Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res, 2013, 19(21): 5822–5827.Nilsson S, Larsen RH, Fossa SD et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res, 2005, 11(12): 4451–4459.Nilsson S, Larsen RH, Fossa SD et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res, 2005, 11(12): 4451–4459.Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A et al. A randomized, doseresponse, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castrationresistant prostate cancer. Eur J Cancer, 2012, 48(5): 678–686.Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A et al. A randomized, doseresponse, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castrationresistant prostate cancer. Eur J Cancer, 2012, 48(5): 678–686.Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist’s perspective. Urology, 2015 Apr, 85(4): 717-724.Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist’s perspective. Urology, 2015 Apr, 85(4): 717-724.Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol, 2013 Feb, 63(2): 189-197.Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol, 2013 Feb, 63(2): 189-197.Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol, 2007 Jul, 8(7): 587-594.Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol, 2007 Jul, 8(7): 587-594.Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 2013 Jul, 18, 369(3): 213-223.Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 2013 Jul, 18, 369(3): 213-223.Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E et al. 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori, 2018, 4: 1-9. doi: 10.1177/0300891618765571.Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E et al. 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori, 2018, 4: 1-9. doi: 10.1177/0300891618765571.

The authors declare that there are no conflicts of interest present.